Short Interest in Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF) Expands By 44.9%

Key Points

• Short interest in Newron Pharmaceuticals rose 44.9% in April to 162,794 shares (about 0.9% of shares sold short), producing an unusually high short-interest ratio of 6,511.8 days due to an average daily volume of just 25 shares.
• The stock opened at $20.00 (a one-year high), with a 50-day moving average of $13.62 and a 200-day moving average of $10.86, up from a one-year low of $9.10.
• Newron is a clinical-stage biopharmaceutical company focused on CNS disorders; its lead product is safinamide, marketed as Xadago, for adjunctive treatment of mid- to late-stage Parkinson’s disease.

Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF - Get Free Report) saw a significant growth in short interest in the month of April. As of April 15th, there was short interest totaling 162,794 shares, a growth of 44.9% from the March 31st total of 112,375 shares. Based on an average trading volume of 25 shares, the short-interest ratio is presently 6,511.8 days. Approximately 0.9% of the shares of the company are sold short.

Newron Pharmaceuticals Stock Performance

Newron Pharmaceuticals stock opened at $20.00 on Tuesday. Newron Pharmaceuticals has a one year low of $9.10 and a one year high of $20.00. The stock has a fifty day moving average of $13.62 and a 200 day moving average of $10.86.

About Newron Pharmaceuticals

Newron Pharmaceuticals SpA is a clinical-stage biopharmaceutical company headquartered in Bresso, Italy, dedicated to developing novel therapies for central nervous system (CNS) disorders. The company's research and development efforts focus on small-molecule compounds designed to address unmet medical needs in neurology and psychiatry.

Newron's lead product, safinamide, is marketed under the brand name Xadago as an adjunctive therapy for patients with mid- to late-stage Parkinson's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.